Email updates

Keep up to date with the latest news and content from BMC Cancer and BioMed Central.

Open Access Highly Accessed Research article

FGFR1 and WT1 are markers of human prostate cancer progression

Elizabeth Devilard1*, Franck Bladou2, Olivier Ramuz3, Gilles Karsenty2, Jean-Philippe Dalès45, Gwenaëlle Gravis6, Catherine Nguyen7, François Bertucci156, Luc Xerri135 and Daniel Birnbaum1*

Author Affiliations

1 Centre de Recherche en Cancérologie de Marseille, Département d'Oncologie Moléculaire, UMR599 Inserm et Institut Paoli-Calmettes, Marseille, France

2 Département d'Urologie, Hôpital Salvator, Marseille, France

3 Département de Biopathologie, Institut Paoli-Calmettes, Marseille, France

4 Département de Pathologie, Hôpital Nord, Marseille, France

5 Faculté de Médecine, Université de la Méditerranée, Marseille, France

6 Département d'Oncologie Médicale, Institut Paoli-Calmettes, Marseille, France

7 Laboratoire TAGC, ERM206, Marseille-Luminy, France

For all author emails, please log on.

BMC Cancer 2006, 6:272  doi:10.1186/1471-2407-6-272

Published: 30 November 2006

Abstract

Background

Androgen-independent prostate adenocarcinomas are responsible for about 6% of overall cancer deaths in men.

Methods

We used DNA microarrays to identify genes related to the transition between androgen-dependent and androgen-independent stages in the LuCaP 23.1 xenograft model of prostate adenocarcinoma. The expression of the proteins encoded by these genes was then assessed by immunohistochemistry on tissue microarrays (TMA) including human prostate carcinoma samples issued from 85 patients who had undergone radical prostatectomy.

Results

FGFR1, TACC1 and WT1 gene expression levels were associated with the androgen-independent stage in xenografts and human prostate carcinoma samples. MART1 protein expression was correlated with pT2 tumor stages.

Conclusion

Our results suggest that each of these four genes may play a role, or at least reflect a stage of prostate carcinoma growth/development/progression.